Status:
TERMINATED
High Intensity Interval Training and Technologies in COPD
Lead Sponsor:
Hull University Teaching Hospitals NHS Trust
Conditions:
COPD
Eligibility:
All Genders
30-90 years
Phase:
NA
Brief Summary
Trials in COPD have shown that HIIT leads to the same positive outcomes as constant load training but causes less breathlessness and leg discomfort during training. However, HIIT protocols in existing...
Detailed Description
Chronic Obstructive Pulmonary Disease (COPD) is a common and disabling smoking-related lung disease that is predicted to become the 3rd leading cause of death world-wide by 2030 (WHO, 2017). The econo...
Eligibility Criteria
Inclusion
- Mild, Moderate and severe\* COPD forced expired volume (FEV-1) ≥30 with an FEV-1/ forced vital capacity (FVC) ratio \<70%) confirmed on spirometry within 6 months of recruitment.
- Chronic breathlessness that limits exercise capacity (mMRC ≥2).
- Using inhaled therapy for COPD including a long-acting bronchodilator agonist (LABA and/or long acting muscarinic agonist (LAMA) with or without inhaled corticosteroids (ICS).
- Oxygen saturations ≥90% breathing room air.
- Willing and able to undertake study procedures.
- Has provided informed consent. \* Mild and Moderate COPD patients will be recruited from the start of the study. A review of exercise session completion rates and adverse events will be performed after 10 patients have been recruited to assess the tolerability and acceptability of the different HIIT protocols prior to beginning recruitment of people with severe COPD
Exclusion
- Significant physical or psychological comorbidity considered by the investigator likely to affect study outcomes.
- Active cardiovascular disease or recent significant cardiovascular event (myocardial infarction within 6 months, cardiac arrhythmias including atrial fibrillation/flutter within 6 months, unstable angina within 6 months, stable angina with current symptoms).
- Moderate or severe COPD exacerbation within 4 weeks of screening (an exacerbation requiring treatment with steroids and/or antibiotics or leading to hospitalisation).
- Unable or unwilling to undertake exercise as set out in the study protocol
Key Trial Info
Start Date :
May 8 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 25 2022
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT05343949
Start Date
May 8 2019
End Date
November 25 2022
Last Update
April 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Castle Hill Hospital
Cottingham, East Yorkshire, United Kingdom, HU16 5JQ